Brent Vaughan

CEO | Cognito Therapeutics

Brent Vaughan is Chief Executive Officer of Cognito Therapeutics, a leading precision neurotechnology company developing disease-modifying therapeutic interventions in neurodegenerative diseases. The company’s lead program is in pivotal studies for Alzheimer’s Disease. Brent has more than 20 years of experience as a serial founder and leader of teams developing proprietary technologies and innovative healthcare products across pharmaceuticals, medical devices, and digital therapeutics. Prior to Cognito, Brent was Chief Executive Officer and Co-Founder at Cognoa, an AI-based pediatric behavioral health company that was awarded two FDA Breakthrough Designations and FDA clearance for its first-in-class lead product. Brent has been fortunate to be part of building great teams and advancing products to meet unmet medical needs in both therapeutic and medical device companies including Kuzani Pharmaceuticals, WellnessFX, Saegis Pharmaceuticals, Nektar Therapeutics, and Roche. Brent is an avid skier, sailor, and enjoys spending time with his family and being outdoors.

All Sessions by Brent Vaughan

  • October 18, 2023


  • 11:15 AM  - 11:55 AM
    Neuromodulation technologies have elicited strong expectations from investors. As products begin to close on commercial stages, companies are finding ways to work with physicians and patients to ensure these new tools can deliver. In this panel three executives from leaders in the space will share how they’re moving to build out the market for neuromodulation technologies.
    Bringing Devices to Market
    Where
    Room 210




Share

Brent Vaughan